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ABSTRACT
Gliosarcomas are a rare subtype of glioblastomas associated with high rates of malignancy-associated
venous thromboembolism (VTE). VTE risk is further increased in hypercoagulable patients upon
discontinuing pharmacologic anticoagulation for surgery. We present a 60-year old obese male with
history of hypercoagulability on apixaban who developed extensive thrombosis following resection of a
gliosarcoma. Prior to temporal lobe resection, apixaban was discontinued and an IVC filter placed. On
postoperative day 4, imaging revealed thrombosis above the IVC filter extending to the bilateral common,
internal and external iliac, and femoral veins, requiring immediate anticoagulation and suction
thrombectomy. Clinicians must balance the risk of VTE and intracerebral hemorrhage following
neurosurgical procedures. While withholding pharmacologic VTE is standard, hypercoagulable patients
may benefit from earlier institution of pharmacologic prophylaxis postoperatively. Patients with multiple
risk factors including malignancies with high rates VTE, like gliosarcomas with medical and
hematological conditions that predispose to clotting, including idiopathic erythrocytosis and history of
VTE may benefit from earlier pharmacologic prophylaxis.
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INTRODUCTION

Glioblastomas are the most common primary malignant brain tumors in adults with a median age of
diagnosis around 55-60 years old. A rare histopathologic subtype of glioblastomas are gliosarcomas, an
isocitrate dehydrogenase wild type glioblastoma, comprising approximately 2-3% of all WHO Grade IV
primary glioblastomas.

1,2

All glioblastomas are derived from astrocytes, the most common type of glial cell. Glioblastomas are a
heterogenous group of malignant tumors without a common genetic signature and varied histopathology,
location, and genetic mutations.3 The gliosarcoma variation of glioblastomas can occur sporadically as a
primary malignancy, or be a secondary malignancy following radiation to the brain.4 Gliosarcomas display
biphasic histopathology, containing gliomatous differentiation, present in all glioblastomas, as well as
mesenchymal components, classically associated with sarcomas, and high grade malignant cells with areas
of necrosis, mitosis and atypia.5 These mesenchymal components resemble histopathology associated with
liposarcoma, chondrosarcoma, and osteosarcomas.6,7 Clinically, gliosarcomas have been traditionally
viewed similarly to other grade IV glioblastomas, sharing similar rates of survival, response to treatments,
and rates of recurrence.8–10
A challenging aspect of management shared by glioblastomas and gliosarcomas is the risk of venous
thromboembolism (VTE), especially after neurosurgical intervention. Malignancies dramatically increase
the risk of VTE by more than five-fold, with 30% of all VTE occurring in the setting of malignancy.11,12
The rate of VTE in high grade gliomas is 20-30%, and as high as 25-39% in patients with high grade
glioblastoma.

11,13

Pharmacologic prophylaxis and intervention for postoperative VTE is complicated

following intracranial surgery. The risk of VTE must be weighed against the risk anticoagulation leading
to intracerebral hemorrhage (ICH), which occurs in nearly 2% of patients following intracranial tumor
resection.14
We present a case of a patient with a history of hypercoagulability and deep vein thrombosis (DVT) in the
setting of idiopathic erythrocytosis on chronic anticoagulation who developed extensive VTE after
resection of a grade IV gliosarcoma.
Case Report
A 60-year-old obese male with a history of hypertension, diabetes mellitus, idiopathic erythrocytosis
requiring intermittent phlebotomy and DVT in the setting of erythrocytosis, currently on apixaban
presented to the emergency department with a two-week history of unilateral, pulsating, temporal
headaches, which progressed to 10/10 pain on the day of admission. Associated symptoms include nausea,
blurry vision, and difficulty with ambulation. Of note, the idiopathic erythrocytosis work up eight years
ago for genetic and paraneoplastic etiologies was inconclusive; negative for JAK2, MPL, and calreticulin
https://rdw.rowan.edu/crjcsm/vol3/iss1/2
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mutations and no renal or liver masses were present. Three years ago, the patient developed a lower
extremity DVT secondary to erythrocytosis, underwent a thrombectomy and has been on apixaban for
future DVT prophylaxis.
On physical exam, no focal neurological deficits were appreciated, however the fundoscopic exam
revealed bilateral papilledema. A non-contrast CT head showed a 3.8 cm right temporal mass with
vasogenic edema and 0.4 cm right to left midline shift. A follow-up magnetic resonance imaging
demonstrated an enhancing cystic and solid mass, and neurosurgical resection as deemed necessary
(Figure 1). A right temporal craniectomy with resection of the temporal lobe mass was performed.
Histopathological analysis of the specimen demonstrated a biphasic malignant tumor with a mixture of
gliomatous and mesenchymal components. The glial component showed gemistocytic areas, epithelioid
morphology, and primitive cellular areas with a high nuclear to cytoplasmic ratio. The mesenchymal
component represented spindle cell sarcoma that was reticulin rich on histochemical staining, which was
consistent with WHO Grade IV gliosarcoma. Prior to his operation, apixaban was held and a retrievable
inferior vena cava (IVC) filter was placed for VTE prophylaxis. Following the resection, the patient had no
neurological deficits, and remained on mechanical VTE prophylaxis. The patient was not restarted on
pharmaceutical anticoagulation due to the potential risk of ICH causing a catastrophic bleed. Additionally,
he received a unit of platelets on postoperative day three due to thrombocytopenia following neurosurgery
with a citrate tube platelet count of 77x103/uL, decreased from 263x103/uL on admission.
On postoperative day three, the patient endorsed new onset leg discomfort. Lower extremity venous
duplex ultrasound on postoperative day four, revealed occlusive thrombosis of the bilateral common
femoral, superficial femoral, popliteal and great saphenous veins. The patient was placed on an
unfractionated heparin drip after risks of VTE was determined to be greater than ICH. On postoperative
day seven, the patient was switched to low molecular weight heparin (LMWH), and interventional
radiology attempted to retrieve the IVC filter but was unsuccessful due to extensive thrombosis of the
abdominal and pelvic vessels. Subsequent CT venogram revealed nonocclusive thrombosis of the
juxtarenal IVC, above the level of the IVC with extension distally to the bifurcation of the iliac veins and
bilateral common iliac, internal and external iliacs, and common femoral veins (Figure 2). Suction
thrombectomy was performed on postoperative day nine to mitigate risk of pulmonary embolism. Of note,
during this admission the patient’s blood glucose levels were difficult to control, and consistently
persistently greater than 250 mg/dL in the postoperative period.
The patient was discharged on postoperative day 11 on therapeutic LMWH. LMWH was chosen in place
of a direct oral anticoagulation due to the risk of future neurosurgical intervention and availability of a
reversal agent. He is continuing his care with neurosurgery and radiation oncology, feeling well and has
Published by Rowan Digital Works, 2021
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not developed any further VTE since discharge.

DISCUSSION

Gliosarcomas are a rare subtype of glioblastomas occurring in a similar patient demographic, with unique
histopathological features, and a grim prognosis.

9,10

The histological and radiographic findings seen in our

patient are consistent with the classical appearance of gliosarcoma as reported in literature.14,15
The temporal lobe is the most common location, commonly seen with surrounding vasogenic edema on
imaging as seen in our patient.4 Immunohistological stains showed glial component that was rich in glial
fibrillary acidic protein (GFAP). The mesenchymal components showed spindle cell sarcoma rich in
reticulin and poor in GFAP. P53 is about 23% mutated in gliosarcoma and in our patient p53 was not
mutated.15
The development of VTE is a common complication in patients with any malignancy, but particularly high
grade glioblastomas and gliosarcomas.12,13 The postoperative complications that occurred in our patient
highlights the difficult management decisions that must be made while caring for these patients. Chemical
VTE prophylaxis is challenging in high grade gliomas resections as current American Society of Clinical
Oncology guidelines recommend pre- and post-surgery chemical VTE prophylaxis in cancer patients.16
However, preoperatively, chemical prophylaxis for neurosurgical procedures has been shown to increase
the risk of intraoperative bleeding.17 Therefore, postoperatively, mechanical prophylaxis alone is often
preferred by neurosurgeons because of the reduced risk of developing ICH when compared to chemical
prophylaxis. An alternative approach to prevention of VTE is the placement of an IVC filter. However,
recent data has shown that chemical prophylaxis combined with mechanical prophylaxis is superior to IVC
filters and does not increase the risk of ICH when administered 24 hours after surgery.18 In addition,
extensive thrombosis of the IVC filter can occur without chemical prophylaxis and removal of thrombi can
potential put those patients at higher risk for adverse events. The risk of clot removal might outweigh the
benefit of its placement.19
Risk factors for thrombosis, in addition to the underlying malignancy, must be considered. Prolonged
immobilization in the postoperative period and history of VTE are strong risk factors for subsequent
development of VTE. Obesity and diabetes are two comorbidities further increasing the patients risk of
VTE. These conditions create a proinflammatory state, propagating a prothrombotic state through
decreasing platelet inhibition, increasing oxidative stress, and increasing platelet activation.20
Unfortunately, literature on the management of patients with underlying hypercoagulable state undergoing
intracranial surgery is limited. Our case report is unique due to the patient’s underlying hypercoagulable
further complicated by gliosarcoma, and subsequent development of extensive postoperative VTE despite
https://rdw.rowan.edu/crjcsm/vol3/iss1/2
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mechanical prophylaxis. The development of such extensive clot burden within four days of discontinuing
chemical VTE prophylaxis illustrates the difficulty of balancing the risk of VTE and ICH. While
withholding chemical prophylaxis postoperatively is the standard, this case suggests patients with multiple
underlying hypercoagulable states and risk factors including prior DVTs, idiopathic erythrocytosis or
additional hematological and underlying medical comorbidities, and malignancies with high rates of VTE,
may experience lower rates of morbidity with more aggressive postoperative pharmacologic
anticoagulation. Postoperative pharmacologic anticoagulation should be done using an agent with an
accessible reversal agent is paramount due to the risk of ICH.

CONCLUSION

The treatment and management of patients with high grade glioblastomas and gliosarcomas is challenging
and can be further complicated by underlying medical comorbidities. VTE are common complications
occurring in all cancer patients, particularly postoperatively, and hematological comorbidities inducing a
hypercoagulable state may necessitate more aggressive VTE prophylaxis. The risk of bleeding must be
weighed against the risk of VTE, and the anticoagulant chosen with the potential need for reversal in mind.
Multiple hypercoagulable risk factors work synergistically, increasing risk of VTE by several fold. As
such, patients with multiple hypercoagulable risk factors may benefit from more aggressive prophylaxis
following intracranial mass resection than patients without other hypercoagulable state inducing
comorbidities.
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Figure 1 Right temporalgliosarcoma on magnetic resonance imaging seen in (A) Axial FLAIR and (B) T2-weighted
coronal section
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Figure 2 Fluoroscopy Showing Inferior Vena Cava Thrombosis during Attempted IVC Filter Removal
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